What is the projected market valuation of the Glucagon Market by 2035?

The Glucagon Market is projected to reach a valuation of 18.42 USD Billion by 2035. Read More

What was the market valuation of the Glucagon Market in 2024?

In 2024, the Glucagon Market was valued at 9.007 USD Billion. Read More

What is the expected CAGR for the Glucagon Market during the forecast period 2025 - 2035?

The expected CAGR for the Glucagon Market during the forecast period 2025 - 2035 is 6.72%. Read More

Which companies are considered key players in the Glucagon Market?

Key players in the Glucagon Market include Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Amgen, Pfizer, Bristol-Myers Squibb, and Mylan. Read More

What are the projected values for the Hypoglycemia segment by 2035?

The Hypoglycemia segment is projected to reach values between 7.5 USD Billion by 2035. Read More

How does the Intravenous route of administration perform in the Glucagon Market?

The Intravenous route of administration is expected to grow to a value of 5.0 USD Billion by 2035. Read More

What is the anticipated market performance for synthetic glucagon by 2035?

Synthetic glucagon is projected to achieve a market value of 6.0 USD Billion by 2035. Read More

What dosage form is expected to dominate the Glucagon Market by 2035?

Injectable dosage forms are anticipated to dominate the market, reaching 11.5 USD Billion by 2035. Read More

What is the projected market value for the Diabetic Ketoacidosis segment by 2035?

The Diabetic Ketoacidosis segment is projected to reach a value of 5.5 USD Billion by 2035. Read More

What trends are influencing the growth of the Glucagon Market?

The growth of the Glucagon Market is influenced by increasing incidences of diabetes and advancements in glucagon formulations. Read More

Glucagon Market

ID: MRFR/HC/28295-HCR

128 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Glucagon Market Research Report By Indication (Hypoglycemia, Diabetic Ketoacidosis, Other Indications), By Route of Administration (Intravenous, Subcutaneous, Intramuscular), By Glucagon Origin (Human, Synthetic, Animal-derived), By Dosage Form (Injectable, Nasal Spray, Other Dosage Forms) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Indication (USD Billion)
  1. 4.1.1 Hypoglycemia
  2. 4.1.2 Diabetic Ketoacidosis
  3. 4.1.3 Other Indications
2. 4.2 Healthcare, BY Route of Administration (USD Billion)
  1. 4.2.1 Intravenous
  2. 4.2.2 Subcutaneous
  3. 4.2.3 Intramuscular
3. 4.3 Healthcare, BY Glucagon Origin (USD Billion)
  1. 4.3.1 Human
  2. 4.3.2 Synthetic
  3. 4.3.3 Animal-derived
4. 4.4 Healthcare, BY Dosage Form (USD Billion)
  1. 4.4.1 Injectable
  2. 4.4.2 Nasal Spray
  3. 4.4.3 Other Dosage Forms
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novo Nordisk (DK)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Sanofi (FR)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boehringer Ingelheim (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Mylan (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY INDICATION
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY GLUCAGON ORIGIN
6. 6.6 US MARKET ANALYSIS BY DOSAGE FORM
7. 6.7 CANADA MARKET ANALYSIS BY INDICATION
8. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
9. 6.9 CANADA MARKET ANALYSIS BY GLUCAGON ORIGIN
10. 6.10 CANADA MARKET ANALYSIS BY DOSAGE FORM
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY INDICATION
13. 6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
14. 6.14 GERMANY MARKET ANALYSIS BY GLUCAGON ORIGIN
15. 6.15 GERMANY MARKET ANALYSIS BY DOSAGE FORM
16. 6.16 UK MARKET ANALYSIS BY INDICATION
17. 6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
18. 6.18 UK MARKET ANALYSIS BY GLUCAGON ORIGIN
19. 6.19 UK MARKET ANALYSIS BY DOSAGE FORM
20. 6.20 FRANCE MARKET ANALYSIS BY INDICATION
21. 6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
22. 6.22 FRANCE MARKET ANALYSIS BY GLUCAGON ORIGIN
23. 6.23 FRANCE MARKET ANALYSIS BY DOSAGE FORM
24. 6.24 RUSSIA MARKET ANALYSIS BY INDICATION
25. 6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
26. 6.26 RUSSIA MARKET ANALYSIS BY GLUCAGON ORIGIN
27. 6.27 RUSSIA MARKET ANALYSIS BY DOSAGE FORM
28. 6.28 ITALY MARKET ANALYSIS BY INDICATION
29. 6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
30. 6.30 ITALY MARKET ANALYSIS BY GLUCAGON ORIGIN
31. 6.31 ITALY MARKET ANALYSIS BY DOSAGE FORM
32. 6.32 SPAIN MARKET ANALYSIS BY INDICATION
33. 6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
34. 6.34 SPAIN MARKET ANALYSIS BY GLUCAGON ORIGIN
35. 6.35 SPAIN MARKET ANALYSIS BY DOSAGE FORM
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY INDICATION
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY GLUCAGON ORIGIN
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY DOSAGE FORM
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY INDICATION
42. 6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
43. 6.43 CHINA MARKET ANALYSIS BY GLUCAGON ORIGIN
44. 6.44 CHINA MARKET ANALYSIS BY DOSAGE FORM
45. 6.45 INDIA MARKET ANALYSIS BY INDICATION
46. 6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
47. 6.47 INDIA MARKET ANALYSIS BY GLUCAGON ORIGIN
48. 6.48 INDIA MARKET ANALYSIS BY DOSAGE FORM
49. 6.49 JAPAN MARKET ANALYSIS BY INDICATION
50. 6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
51. 6.51 JAPAN MARKET ANALYSIS BY GLUCAGON ORIGIN
52. 6.52 JAPAN MARKET ANALYSIS BY DOSAGE FORM
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY INDICATION
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY GLUCAGON ORIGIN
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM
57. 6.57 MALAYSIA MARKET ANALYSIS BY INDICATION
58. 6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
59. 6.59 MALAYSIA MARKET ANALYSIS BY GLUCAGON ORIGIN
60. 6.60 MALAYSIA MARKET ANALYSIS BY DOSAGE FORM
61. 6.61 THAILAND MARKET ANALYSIS BY INDICATION
62. 6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
63. 6.63 THAILAND MARKET ANALYSIS BY GLUCAGON ORIGIN
64. 6.64 THAILAND MARKET ANALYSIS BY DOSAGE FORM
65. 6.65 INDONESIA MARKET ANALYSIS BY INDICATION
66. 6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
67. 6.67 INDONESIA MARKET ANALYSIS BY GLUCAGON ORIGIN
68. 6.68 INDONESIA MARKET ANALYSIS BY DOSAGE FORM
69. 6.69 REST OF APAC MARKET ANALYSIS BY INDICATION
70. 6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
71. 6.71 REST OF APAC MARKET ANALYSIS BY GLUCAGON ORIGIN
72. 6.72 REST OF APAC MARKET ANALYSIS BY DOSAGE FORM
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY INDICATION
75. 6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
76. 6.76 BRAZIL MARKET ANALYSIS BY GLUCAGON ORIGIN
77. 6.77 BRAZIL MARKET ANALYSIS BY DOSAGE FORM
78. 6.78 MEXICO MARKET ANALYSIS BY INDICATION
79. 6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
80. 6.80 MEXICO MARKET ANALYSIS BY GLUCAGON ORIGIN
81. 6.81 MEXICO MARKET ANALYSIS BY DOSAGE FORM
82. 6.82 ARGENTINA MARKET ANALYSIS BY INDICATION
83. 6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
84. 6.84 ARGENTINA MARKET ANALYSIS BY GLUCAGON ORIGIN
85. 6.85 ARGENTINA MARKET ANALYSIS BY DOSAGE FORM
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY GLUCAGON ORIGIN
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE FORM
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY GLUCAGON ORIGIN
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE FORM
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY GLUCAGON ORIGIN
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE FORM
99. 6.99 REST OF MEA MARKET ANALYSIS BY INDICATION
100. 6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
101. 6.101 REST OF MEA MARKET ANALYSIS BY GLUCAGON ORIGIN
102. 6.102 REST OF MEA MARKET ANALYSIS BY DOSAGE FORM
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY GLUCAGON ORIGIN, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY GLUCAGON ORIGIN, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY DOSAGE FORM, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY DOSAGE FORM, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.2.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.3.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.4.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.5.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.6.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.7.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.8.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.9.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.10.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.11.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.12.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.13.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.14.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.15.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.16.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.17.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.18.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.19.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.20.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.21.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.22.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.23.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.24.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.25.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.26.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.27.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.28.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.29.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY INDICATION, 2025-2035 (USD Billion)
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY GLUCAGON ORIGIN, 2025-2035 (USD Billion)
  4. 7.30.4 BY DOSAGE FORM, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Glucagon Market Segmentation

Glucagon Market By Indication (USD Billion, 2025-2035)

Hypoglycemia
Diabetic Ketoacidosis
Other Indications

Glucagon Market By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Intramuscular

Glucagon Market By Glucagon Origin (USD Billion, 2025-2035)

Human
Synthetic
Animal-derived

Glucagon Market By Dosage Form (USD Billion, 2025-2035)

Injectable
Nasal Spray
Other Dosage Forms

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”